Evidence map›Paper›PMID 36387074›Full record

ArticleFrontiers in oncology2022

A case report of primary cardiac angiosarcoma with

Kun Tian, Yating Liu, Haiying Zhu, Tao Wang, Tianxing Chen, Xiaxia Pei, Feixue Song

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kun TianDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Yating LiuDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Haiying ZhuDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Tao WangDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Tianxing ChenDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Xiaxia PeiDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Feixue SongDepartment of Medical Oncology, Second Hospital of Lanzhou University, Lanzhou, China.
Lanzhou University Second Hospital · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac angiosarcoma is a rare disease with a high mortality rate despite its low incidence. Surgery is currently the mainstay treatment strategy for patients with this condition. Herein, we describe a case of primary cardiac angiosarcoma, including symptoms, examination findings, treatment strategy and prognosis. In 2020, the patient was admitted to our hospital, and Next-Generation Sequencing (NGS) revealed a mutation in the

Indexed as

cardiac angiosarcomacardiac tumor rupturechemotherapyDNMT3Asurgery

Identifiers

PMID36387074
PMCPMC9647023
OpenAlexW4307633853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.